Floatz logo

EXEMESTANE

Progesterone Receptor Positive Tumor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSSmall moleculePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Progesterone Receptor Positive Tumor cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Oana Danciu, MD
Phase 3BB
Palbociclib
Oana Danciu, MD
Phase 2B
Cyclophosphamide
Virginia Commonwealth University
Phase 2CCC
Decitabine
Virginia Commonwealth University
Phase 2CCC
Inno-206
Virginia Commonwealth University
Phase 2CCC

View all 12 →

Same molecule, other indications

EXEMESTANE is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
ER+ Breast CancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →